Acute Myeloid Leukemia Clinical Trial
Official title:
A Phase I/II National, Open-label, Multicenter Study of Bortezomib (Velcade) in Combination With FLAG-IDA (VFLAG- IDA) in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML).
The primary aim of this study is:
• To analyze the efficacy (in order to evaluate the response) of a sequential treatment
scheme of Bortezomib in combination with Fludarabine,Cytarabine and Idarubicin continued
with Bortezomib monotherapy for patients with relapsed or refractory AML ≥18 years old.
The safety aim of this study is:
• To evaluate the safety and tolerance of the sequential treatment scheme proposed with
Bortezomib combined with Fludarabine, Cytarabine and Idarubicin and in monotherapy, measured
on clinical toxicities and laboratory incidences.
The biological aim of this study is:
• To evaluate the Minimal Residual Disease (MRD)impact that will be monitored by
multiparametric flow cytometry carried out at different moments during the treatment.
Initially a phase I will be performed to determine the appropriate dose of Cytarabine to be
used in Flag-Ida regimen in combination with Velcade; for that reason, first 9 patients will
be distributed to 3 different cohorts with 3 patients in each cohort, which will be treated
at each Cytarabine dose level (200 mg/m2-500 mg/m2-1000 mg/m2)in combination with the other
drugs from Flag scheme and the fixed dose of Velcade at 1,3 mg/m2.
Once the appropriate Cytarabine dose is determined,the recruitment will be completed with 40
patients and evaluations and visits program will be realized in three periods:
Pre-treatment, Treatment and Follow-up.
The Pre-treatment includes Screening and baseline visits. After providing informed consent,
patients will be evaluated for study eligibility.
Eligible patients included in the study will receive the first cycle, which consist of
Fludarabine, Cytarabine and Idarubicin in combination with 2 times per week of Velcade
administration. Each 28-day treatment, patients will be evaluated, and in absence of disease
progression or unacceptable toxicity, patients will start second cycle with Bortezomib in
monotherapy two times per week followed by a 10 days rest period. That is, patients who
response with acceptable toxicity will receive the combined sequential scheme twice (as
induction and consolidation).
Patients will be evaluated the day 1 of each cycle,during the treatment period, in order to
know the response before carrying on the treatment. Once the Treatment period is completed,
patients will be evaluated during the Follow-up period, one monthly visit in year 1, and
every 3 months for 3 next years. On each center criteria, autologous/allogeneic transplant
can be planned depending on age and HLA identical sibling donor make it possible: it will be
done following the sequential scheme (Velcade-Flag-Ida and Velcade in monotherapy); if the
patient is not candidate for a transplant or has no donor, he/she will receive 2 sequential
scheme.
Safety will be evaluated through all adverse events monitoring, physical exploration, vital
signs, hematimetric and biochemical analysis. The treatment response will be evaluated using
Cheson's standardized criteria, and MRD impact will be necessary evaluated the day 1 of each
new cycle before to carry on the treatment.
;
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Recruiting |
NCT04460235 -
Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma
|
Phase 4 | |
Completed |
NCT03678493 -
A Study of FMT in Patients With AML Allo HSCT in Recipients
|
Phase 2 | |
Completed |
NCT04022785 -
PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
Recruiting |
NCT05424562 -
A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
|
||
Terminated |
NCT03224819 -
Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML)
|
Early Phase 1 | |
Completed |
NCT03197714 -
Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia
|
Phase 1 | |
Active, not recruiting |
NCT04070768 -
Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Active, not recruiting |
NCT04107727 -
Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML)
|
Phase 2 | |
Recruiting |
NCT04385290 -
Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04920500 -
Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients
|
N/A | |
Recruiting |
NCT03897127 -
Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics
|
Phase 3 | |
Active, not recruiting |
NCT04021368 -
RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome
|
Phase 1 | |
Recruiting |
NCT03665480 -
The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML
|
Phase 2/Phase 3 | |
Completed |
NCT02485535 -
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant
|
Phase 1 | |
Enrolling by invitation |
NCT04093570 -
A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers
|
Phase 2 | |
Recruiting |
NCT04069208 -
IA14 Induction in Young Acute Myeloid Leukemia
|
Phase 2 | |
Recruiting |
NCT05744739 -
Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)
|
Phase 1 | |
Recruiting |
NCT04969601 -
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
|
Phase 1/Phase 2 |